The global Animal Model Market continues to demonstrate robust expansion, supported by rising investments in biomedical research, pharmaceutical innovation, and translational medicine. The Animal model Market Size was valued at USD 2.3 billion in 2023 and is projected to reach USD 4.6 billion by 2032, growing at a CAGR of 8.2% during the forecast period from 2024 to 2032. This sustained growth reflects the essential role animal models play in understanding complex human diseases and accelerating the development of safe and effective therapies.
According to industry analysis, the Animal model Market benefits from increased demand across oncology, genetic research, neuroscience, and immunology. Animal-based preclinical studies remain a regulatory cornerstone, enabling researchers to evaluate efficacy, toxicity, and pharmacokinetics before advancing compounds to human trials. The market’s momentum is further reinforced by growing government funding, expanding pharmaceutical pipelines, and technological advancements in genetically modified models.
Get free Sample Report@ https://www.snsinsider.com/sample-request/3789
Growing Dominance of Mice in Biomedical Research
By animal type, mice accounted for the largest revenue share of 51% in 2023, underscoring their unmatched relevance in biomedical research. Their genetic similarity to humans continues to make them indispensable, with approximately 75% of genes responsible for human diseases also present in mice, according to data referenced by leading biomedical research institutions. Regulatory data further indicates that over 65% of preclinical trials approved in 2023 involved mouse models, highlighting their widespread acceptance in safety and efficacy testing.
The growing adoption of transgenic and knockout mice also contributed significantly to market expansion. Research activity in these advanced mouse models increased by 18% in 2023, driven by demand for more precise disease modeling and personalized medicine approaches. Short reproductive cycles, cost efficiency, and reproducibility make mice particularly suitable for long-term and large-scale studies, reinforcing their dominance within the animal model ecosystem.
Cancer Research Leads Application Segments
By application, cancer research emerged as the leading segment, accounting for 41% of total market share in 2023. The increasing global cancer burden has intensified the need for accurate disease models that can replicate tumor development, metastasis, and therapeutic response. With an estimated 1.9 million new cancer cases diagnosed in 2023, research institutions and pharmaceutical companies have accelerated investments in oncology-focused animal studies.
Significant public funding continues to fuel this segment. In 2023, approximately USD 8 billion was invested in cancer research, with more than 40% of funded projects relying on animal models. These models remain critical for evaluating novel therapies, including immunotherapies and targeted treatments. At the same time, improved ethical frameworks and oversight mechanisms have enabled continued use of animal models while reducing overall animal burden through refined experimental protocols.
Pharmaceutical and Biotechnology Companies Drive End-Use Demand
By end use, pharmaceutical and biotechnology companies held the largest share at 38% in 2023, reflecting their heavy reliance on animal models throughout drug discovery and development. Rising research and development spending across the biopharmaceutical sector has strengthened demand for validated preclinical models. Industry data indicates that biopharmaceutical R&D investment grew by 14% between 2022 and 2023, with animal testing remaining a critical step in regulatory submissions.
Over the past decade, more than 100 drugs received regulatory approval, and nearly 60% of them were studied using animal models prior to commercialization. Supportive policy initiatives aimed at accelerating breakthrough therapies have further encouraged preclinical research, indirectly sustaining long-term growth in the animal model market.
North America Leads While Asia-Pacific Shows Fastest Growth
Regionally, North America dominated the market in 2023 with a 43% revenue share, driven by strong government support, advanced research infrastructure, and the presence of leading pharmaceutical and academic institutions. A substantial proportion of federally funded biomedical projects in the region continue to incorporate animal models, particularly for translational and early-stage research.
Meanwhile, the Asia-Pacific region is expected to register the fastest CAGR during the 2024–2032 forecast period. Rapid expansion of pharmaceutical manufacturing, supportive government subsidies, and increased biotechnology funding in countries such as China and India are accelerating adoption. Rising investments in advanced animal models and preclinical capabilities position the region as a key growth engine for the global market. Europe remains an active contributor, supported by evolving regulatory frameworks and a strong focus on ethical research practices.
Outlook
As precision medicine, oncology research, and biologics development continue to advance, animal models are expected to remain a foundational component of preclinical research. Ongoing innovation in genetically engineered models, combined with ethical and regulatory refinements, will play a crucial role in shaping the future of the animal model market through 2032.
Other Trending Reports
Hysteroscopy Instrument Market
Antipsychotic Drugs Market Growth
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Rohan Jadhav – Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
